J
James D. Reimann
Researcher at Genentech
Publications - 12
Citations - 2925
James D. Reimann is an academic researcher from Genentech. The author has contributed to research in topics: Immunoglobulin E & Metastatic breast cancer. The author has an hindex of 9, co-authored 12 publications receiving 2860 citations. Previous affiliations of James D. Reimann include Duke University.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller,Linnea I. Chap,Frankie A. Holmes,Melody A. Cobleigh,P. Kelly Marcom,Louis Fehrenbacher,Maura N. Dickler,Beth Overmoyer,James D. Reimann,Amy P. Sing,Virginia K. Langmuir,Hope S. Rugo +11 more
TL;DR: Although the addition of bevacizumab to capecitabine produced a significant increase in response rates, this did not translate into improved PFS or overall survival.
Journal ArticleDOI
A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer
Melody A. Cobleigh,Virginia K. Langmuir,George W. Sledge,Kathy D. Miller,Latrice Haney,William Novotny,James D. Reimann,Amy Vassel +7 more
TL;DR: The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable, and these data support the initiation of trials in metastatic breast cancer combining bevacszumab with chemotherapy.
Journal ArticleDOI
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
Thomas B. Casale,I.L. Bernstein,William W. Busse,C. LaForce,David G. Tinkelman,R.R. Stoltz,Dockhorn Rj,James D. Reimann,Su Jq,Fick Rb,Daniel C. Adelman +10 more
TL;DR: The results suggest that if given in adequate doses, rhuMAb-E25 should be an effective therapy for allergic diseases.
Journal ArticleDOI
Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial ☆
Kenneth A. Ault,Christopher P. Cannon,Jane Mitchell,John McCahan,Russell P. Tracy,William Novotny,James D. Reimann,Eugene Braunwald +7 more
TL;DR: Although platelet activation decreased after one month of oral GPIIb/IIIa inhibition, levels remained higher than normal, suggesting the need for long-term antiplatelet therapy following ACS.
Journal ArticleDOI
Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,Steven D. Schwartz,Mark S. Blumenkranz,Joan W. Miller,Julia A. Haller,James D. Reimann,William L. Greene,Naveed Shams +7 more
TL;DR: Single intravitreal injections of ranibizumab up to a dose of 500 microg were safe and well tolerated in this small group of patients, and the maximum tolerated single dose in neovascular AMD patients was 500microg.